Neurology Specific Literature Search   
 
[home][thesaurus]
    

Enter your terms
above and click
the 'Search' button.
Showing articles 0 to 35 of 35

Filter Applied: monoclonal antibodies (Click to remove)

Infectious and Non-Infectious Neurologic Complications in Heart Transplant Recipients
Medicine 89:166-175, Mu�oz,P., et al, 2010

Clinical Presentation, Management, and Outcome in Neurolymphomatosis, A Systematic Review
Neurol 103:e209698, Kaulen.L.D.,et al, 2024

Lecanemab in Early Alzheimers Disease
NEJM 388:9-21,80, van Dyck,A.H.,et al, 2023

GQ1b-Seronegative Miller Fisher Syndrome Associated with Pembrolizumab
J Neuro-Ophthal 39:394-396, Green, K.E.,et al, 2019

Maternal and Fetal Risks of Natalizumab Exposure in Utero
Neurol 90:443-444, Marrie, R.A.,et al, 2018

Acute demyelinating polyneuropathy induced by nivolumab
JNNP 89:435-437, Fukumoto, Y.,et al, 2018

A 77-year-old man presenting with episodic expressive aphasia
Neurol 90:e1822-e1826, Shanklin, A.,et al, 2018

Progressive Multifocal Leukoencephalopathy after Treatment with Nivolumab
Emerg Inf Dis 24:1594-1596, Martinot, M.,et al, 2018

Autoimmune Encephalitides: A Broadening Field of Treatable Conditions
Neurologist 22:1-13, Kalman, B., 2017

Clinicopathologic Conference, Paroxysmal Nocturnal Hemoglobinuria
NEJM 377:2581-2590, Case 40-2017, 2017

Myasthenia Gravis
NEJM 375:2570-2581, Gilhus, N.E.,et al, 2016

Acute Demyelinating Polyneuropathy Caused by Nivolumab in a Man with Metastatic Non-Small Cell Lung Cancer
J Gerontol Geriatr Res 5:3, Sabeeh-Ur-Rehman, B. & Bhaumik, S., 2016

Tumor Necrosis Factor-Alpha Inhibitors: An Overview of Adverse Effects
UpToDate January, Stone, J.H., 2013

Tumor Necrosis Factor-Alpha Inhibitors: Risk of Malignancy
UpToDate January, Stone, J.H., 2013

Neurological Immune-Related Adverse Events of Ipilimumab
Pract Neurol 13:278-280, Bot, I.,et al, 2013

PML-IRIS in a patient treated with Brentuximab
Neurol 79:2075-2077, Geldern, G.,et al, 2012

Rituximab Monotherapy for Patients With Recurrent Primary CNS Lymphoma
Neurol 76:929-930, Batchelor,T.T.,et al, 2011

Primary Central Nervous System Lymphoma in a Patient Treated with Natalizumab
Ann Neurol 69:1060-1062, Phan-Ba, R.,et al, 2011

Opportunistic Infections and Other Risks with Newer Multiple Sclerosis Therapies
Ann Neurol 65:367-377, Berger,J.R. &Houff,S., 2009

Primary Central Nervous System Lymphoma in a Patient Treated with Natalizumab
Ann Neurol 66:403-406, 261, 262, Schweikert,A.,et al, 2009

Natalizumab and Central Nervous System Lymphoma: No Clear Association
Ann Neurol 66:261-262, Bozic,C.,et al, 2009

Emergency Administration of Abciximab for Treatment of Patients With Acute Ischemic Stoke: Results of an International Phase III Trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II)
Stroke 39:89-99, Adams,H.P.,Jr.,et al, 2008

Lymphomatoid Granulomatosis Involving Central Nervous System Successfully Treated With Rituximab alone
Arch Neurol 65:662-665, Ishiura,H.,et al, 2008

Monoclonal Antibody Therapies and Neurologic Disorders
Arch Neurol 65:1162-1165, Novack,J.C.,et al., 2008

Progressive Multifocal Leukoencephalopathy After Rituximab in a Case of Non-Hodgkin Lymphoma
Neurol 69:704-706, Kranick,S.M.,et al, 2007

Intracranial Hemorrhage in Patients Treated with Bevacizumab and Low-Molecular Weight Heparin
Clin Adv Hematol Oncol 5:375-379, Nguyen, T.D.,et al, 2007

Clinicopath Conf, Diffuse Large B-Cell Lymphoma, EBV-Positive, with Immunosuppression
NEJM 354:1178-1184, Case 8-2006, 2006

Salvage Therapy for Primary CNS Lymphoma with a Combination of Rituximab and Temozolomide
Neurol 63:901-903, Enting,R.H.,et al, 2004

Cerebral Toxoplasmosis Following Etanercept Treatment for Idiophatic Pneumonia Syndrome after Autologous Peripheral Blood Progenitor Cell Transplantation (PBPCT)
Ann Hematol 82:649-653, Gonzalez-Vicent, M.,et al, 2003

Aseptic Meningitis Following Cardiac Transplantation:Clinical Characteristics & Relationship to Immunosuppressive Regimen
Neurol 41:249-252, Adair,J.C.,et al, 1991

Treatment of Guillain-Barre Syndrome with Anti-T Cell Monoclonal Antibodies
JNNP 54:51-54, Feasby,T.E., 1991

Neurotoxicity After Treatment with Muromonab-CD3
NEJM 323:487-488, Richards,J.M.,et al, 1990

OKT3 Encephalopathy
Ann Neurol 28:837-838, Coleman,A.E.&Norman,D.J., 1990

Nosocomial Aseptic Meningitis Associated with Administration of OKT3
JAMA 259:2002-2005, Martin,M.A.,et al, 1988

Diagnostic Importance of Immunological Markers in Lymphoma Involving the Central Nervous System
Ann Neurol 16:668-672, Ezrin-Waters,C.,et al, 1984



Showing articles 0 to 35 of 35